Eurofins continued its strong showing with 44.3% organic top-line growth in Q1, building on its robust performance in the second half of last year. The share price came under pressure on the back of qoq lower revenue from COVID-19 clinical testing and reagents, whilst core offerings grew at 10% despite the lockdown measures in key geographies. Management maintained its financial guidance for now, but 2021 appears to exceed the financial objectives materially.
28 Apr 2021
Core business accelerates, while COVID-19 revenue subsides but remains robust
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Core business accelerates, while COVID-19 revenue subsides but remains robust
- Published:
28 Apr 2021 -
Author:
Vansh Mehta -
Pages:
3
Eurofins continued its strong showing with 44.3% organic top-line growth in Q1, building on its robust performance in the second half of last year. The share price came under pressure on the back of qoq lower revenue from COVID-19 clinical testing and reagents, whilst core offerings grew at 10% despite the lockdown measures in key geographies. Management maintained its financial guidance for now, but 2021 appears to exceed the financial objectives materially.